Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor

Journal of Medicinal Chemistry

Volumn 48, Issue 11, 2005, Pages 3684-3687

  Macherla, Venkat R ^a   Mitchell, Scott S ^a   Manam, Rama Rao ^a   Reed, Katherine A ^a   Chao, Ta Hsiang ^a   Nicholson, Benjamin ^a   Deyanat Yazdi, Gordafaried ^a   Mai, Bao ^a   Jensen, Paul R ^b   Fenical, William F ^b   Neuteboom, Saskia T C ^a   Lam, Kin S ^a   Palladino, Michael A ^a   Potts, Barbara C M ^a  

^a Nereus Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROETHANE; CYCLOALKENE; HALOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NPI 0052; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ARTICLE; CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME INHIBITION; EPOXIDATION; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ACTINOBACTERIA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; HUMANS; LACTONES; MARINE BIOLOGY; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLES; RABBITS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20044397059     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm048995+     Document Type: Article

References (15)

1. Adams J. Proteasome Inhibitors in Cancer Therapy; Humana Press: Totowa, NJ, 2004.
2. Richarson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Seigel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
3. Chauhan, D.; Li, G.; Shringarpure, R.; Podar, K.; Ohtake, Y.; Hideshima, T.; Anderson, K. C. Blockade of Hsp27 Overcomes Bortezomib/Proteasome Inhibitor PS-341 Resistance in Lymphoma Cells. Cancer Res. 2003, 63, 6174-6177.
4. Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. F. Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus Salinospora., Angew. Chem., Int. Ed. 2003, 42, 355-357.
5. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Mitsiades, C.; Ovaa, H.; Berkers, C.; Munshi, N.; Chao, T.; Nicholson, B.; Neuteboom, S. T.; Richardson, P.; Palladino, M.; Anderson, K. C. A Novel Non-Peptide and Orally Active Proteasome Inhibitor Overcomes Bortezomib-Resistance in Multiple Myeloma Cells. Cancer Cell, submitted.
6. Wang, C. Y.; Mayo, M. W.; Korneluk, R. G.; Goeddel, D. V.; Baldwin, A. S., Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998, 281, 1680-1683.
7. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Richardson, P. G.; Hideshima, T.; Munshi, N. C.; Treon, S. P.; Anderson, K. C. Apoptotic signaling induced by immunomodulatory thalidomide analogues in human multiple myeloma cells: therapeutic implications. Blood 2002, 99, 4525-4530.
8. Cusack, J. C., Jr.; Liu, R.; Houston, M.; Abendroth, K.; Elliott, P. J.; Adams, J.; Baldwin, A. S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001, 61, 3535-3540.
9. Omura, S.; Matsuzaki, K.; Fujimoto, T.; Kosuge, K.; Furuya, T.; Fujita, S.; Nakagawa, A. Structure of Lactacystin, a New Microbial Metabolite which Induces Differentiation of Neuroblastoma Cells. J. Antibiot. 1991, 44, 117-118.
10. Dick, L. R.; Cruikshank, A. A.; Grenier, L.; Melandri, F. D.; Nunes, S. L.; Stein, R. L. Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin. J. Biol. Chem. 1996, 271, 7273-7276.
11. Corey, E. J.; Li, W. Z. Total Synthesis and Biological Activity of Lactacystin, Omuralide, and Analogues. Chem. Pharm. Bull. 1999, 47, 1-10.
12. Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. Inhibition of Proteasome Activities and Subunit-Specific Amino-Terminal Threonine Modification by Lactacystin. Science 1995, 268, 726-731.
13. Groll, M.; Huber, R. Inhibitors of the Eukaryotic 20S Proteasome Core Particle: A Structural Approach. Biochim. Biophys. Acta 2004, 1695, 33-44.
14. Soucy, F.; Grenier, L.; Behnke, M. L.; Destree, A. T.; McCormack, T. A.; Adams, J.; Plamondon, L. A Novel and Efficient Synthesis of a Highly Active Analogue of clasto-Lactacystin β-lactone. J. Am. Chem. Soc. 1999, 121, 9967-9976.
15. Omuralide has previously been shown to cross the cell membrane. Dick, L. R.; Cruikshank, A. A.; Destree, A. T.; Grenier, L.; McCormack, T. A.; Melandri, F. D.; Nunes, S. L.; Palombella, V. J.; Parent, L. A.; Plamondon, L.; Stein, R. L. Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin in Cultured Cells. J. Biol. Chem. 1997, 272, 182-188.